

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, 9/16, 9/20, 47/48	A1	(11) International Publication Number: WO 97/09980 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/EP96/03719 (22) International Filing Date: 21 August 1996 (21.08.96) (30) Priority Data: 9518953.6 15 September 1995 (15.09.95) GB (71) Applicant (for all designated States except GB JP US): PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. [BE/IE]; La Touche House, International Financial Services Centre, Dublin 1 (IE). (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (71) Applicant (for JP only): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DOLAN, Thomas, Francis [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). HUMPHREY, Michael, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). NICHOLS, Donald, John [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (81) Designated States: AU, BR, CA, CN, CU, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR, US, VN, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN		
(57) Abstract There is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, characterized in that the dosage form is adapted to deliver at least 10 % by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of the patient. The formulation minimizes unwanted side-effects and increases the bioavailability of darifenacin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN

This invention relates to pharmaceutical dosage forms of darifenacin and its pharmaceutically acceptable salts.


5

Darifenacin is (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide and is disclosed in European Patent N° 0388054, Examples 1B and 8, and is referred to therein as 3-(S)-(-)-(1-carbamoyl-1,1-diphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]pyrrolidine. It is indicated in the treatment of urinary incontinence and irritable bowel syndrome and has the following structure:

10



Clinical investigations have shown a major metabolite of darifenacin to be the following 3'-hydroxy derivative:



15 It appears that the metabolite is 6-fold less selective for muscarinic M3 receptors over M1 receptors in comparison with darifenacin, and so the metabolite is more likely than darifenacin to produce unwanted side-effects such as dry mouth, confusion and blurred vision.

20 It has now been found that delivering darifenacin and its pharmaceutically acceptable salts to the lower gastrointestinal tract (e.g. in a sustained release formulation) gives rise to a greater ratio of darifenacin to metabolite in the systemic circulation. This increases the bioavailability of darifenacin, which is likely to minimize any unwanted side-effects. This is surprising because a slower release rate normally leads to a slower delivery to
25 liver enzymes and a greater degree of metabolism of an administered drug.

Thus, according to the present invention, there is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin,

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the dosage form is adapted to deliver at least 10% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of the patient.

5

The dosage forms of the invention may be of the sustained or delayed release type, and so release the darifenacin, or the pharmaceutically acceptable salt thereof, to the gastrointestinal tract of the patient over or after a sustained period of time following administration of the dosage form to the patient. However, when the dosage forms are
10 administered rectally, conventional rectal formulations may be used.

By "lower gastrointestinal tract" is meant the portion of the gastrointestinal tract between the region of the ileo-caecal junction and the rectum inclusive.

15 "Patient" means primarily a human patient, although the formulations of the present invention may be useful in the treatment of non-human animals.

Preferably, the dosage forms of the invention are adapted to deliver at least 25%, and more preferably 50% by weight of the darifenacin, or the pharmaceutically acceptable salt
20 thereof, to the lower gastrointestinal tract.

Preferably, no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released 4 hours after dosing; more preferably no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is
25 released 8 hours after dosing; and most preferably, no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released 16 hours after dosing.

The conditions in the gastrointestinal tract are thought to be reproduced *in vitro* using
30 Apparatus 1 described in USP XXII at page 1578, having baskets of 40 mesh (381µm apertures), a rotation speed of 100 rpm and a dissolution medium of water at 37°C. Therefore, the sustained release formulations of the invention may be defined alternatively as a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof,
35 and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the

dosage form is adapted to release the darifenacin, or the pharmaceutically acceptable salt thereof, in Apparatus 1 described in USP XXII at page 1578, having baskets of 40 mesh (381 μ m apertures), a rotation speed of 100 rpm and a dissolution medium of water at 37°C, over a sustained period of time.

5

Particular oral dosage forms include:

- (a) those in which the darifenacin, or the pharmaceutically acceptable salt thereof, is embedded in a matrix from which it is released by diffusion or erosion;
- (b) those in which the darifenacin, or the pharmaceutically acceptable salt thereof, is present in a multiparticulate core;
- (c) those in which there is an impermeable coating provided with an aperture through which the darifenacin, or the pharmaceutically acceptable salt thereof, is released;
- (d) those in which there is a coating of low aqueous solubility;
- (e) those in which there is a semipermeable coating;
- (f) those in which the darifenacin is present as an ion exchange resin complex; and
- (g) pulsatile devices from which the darifenacin is released at specific points in the gastrointestinal tract.

It will be apparent to those skilled in the art that some of the above means of achieving sustained release may be combined: for example a matrix containing the active compound may be formed into a multiparticulate and/or coated with an impermeable coating provided with an aperture.

Dealing with each category in turn:

- (a) In matrix systems, which are preferred, the active compound is embedded or dispersed in a matrix of another material which serves to retard the release of the active compound into an aqueous environment. Suitable matrix materials include hydroxypropyl methylcellulose and hydroxypropyl cellulose. Matrix formulations according to the present invention preferably comprise high molecular weight (*i.e.* 85,000-95,000 mass units) hydroxypropyl methylcellulose.
- (b) In multiparticulate cores, the active compound is present in a number of particles which also contain adjuvants, diluents or carriers. Suitable adjuvants, diluents and carriers include microcrystalline cellulose (preferably having a particle size of 50 μ m) and lactose (preferably having a particle size equivalent to 110 mesh (137.5 μ m apertures)).

Typically, the blended ingredients are formed into a wet mass which is extruded and spheronized to form beads which are then dried.

(c) Impermeable coatings are applied to tablets containing the active compound.

"Impermeable" means that no significant transport of the active compound can take place

5 across the coating during the intended release period of the formulation. Suitable materials include film-forming polymers and waxes [e.g. thermoplastic polymers such as poly(ethylene-covinyl acetate), poly(vinyl chloride), ethyl cellulose and cellulose acetate] and the coating thickness is preferably greater than 100 μ m. The aperture may be formed by drilling, or if the coated formulation is conical, by cutting off the tip.

10 (d) Coatings of low aqueous solubility include polymers. The solubility of such polymers may be pH-dependent, for example substantially insoluble at pH<5 (so that dissolution does not take part in the stomach) and water soluble at pH>5. Preferred pH-sensitive polymers include shellac, phthalate derivatives (including cellulose acetate phthalate, polyvinylacetate phthalate), polyacrylic acid derivatives, and vinyl acetate and
15 crotonic acid copolymers.

(e) Semipermeable membrane coatings allow the active compound to diffuse across the membrane or through liquid filled pores within the membrane. Suitable coating materials include polymers such as cellulose ester or ether, and acrylic polymers. Preferred materials include ethyl cellulose, cellulose acetate and cellulose acetate
20 butyrate.

(f) Darifenacin resinates may be prepared by treating anionic ion exchange resin beads (for example sodium polystyrene sulphonate) with an acid addition salt of darifenacin.

(g) Pulsatile devices have the capacity to release drug at various points of the
25 gastrointestinal tract. They may depend on osmotic potential to trigger release (see US Patent N° 3,952,741) or erosion of polymeric material due to changes in pH or microbial degradation. Suitable polymeric materials include pectin [Rubinstein *et al*, 1991, Pectic salt as a colonic delivery system, Proceed. Intern. Symp. Control. Rel. Bioact. Mater.], methacrylate-galactomannan [Lehman *et al*, 1991, Methacrylate-galactomannan coating
30 for colonic specific drug delivery, *ibid*], matter containing azobonds [Kopeckova *et al*, 1991, Bioadhesive polymers for colon specific drug delivery, *ibid*], chondroitin [Sintov *et al*, 1991, Colonic administration of indomethacin using modified chondroitin in a cannulated dog model, *ibid*], dextran hydrogels [Bronsted *et al*, 1993, A novel hydrogel system designed for controlled drug delivery to the colon, *ibid*], methacrylic acid copolymers
35 [Siefke *et al*, 1993, β -Cyclodextrin matrix films for colon specific drug delivery, *ibid*], and

amylose [Milojevik *et al*, *In vitro* and *in vivo* evaluation of amylose coated pellets for colon specific drug delivery, *ibid*]. Delivery to specific points of the gastrointestinal tract may also be achieved using multilayered tablets [Gazzaniga *et al*, 1993, Time dependent oral delivery system for colon specific release, *ibid*], or hydrogel plugs in a capsule [Binns *et al*, Application of a pH-independent PEG-based hydrogel to afford pulsatile drug delivery].

Preferably, in the dosage forms of the present invention, the darifenacin is in the form of its hydrobromide salt (except when the darifenacin is present as an ion exchange resin complex).

10

A preferred oral formulation is a tablet consisting essentially of darifenacin hydrobromide in a high molecular weight hydroxypropyl methylcellulose matrix together with anhydrous dibasic calcium phosphate and magnesium stearate. The tablet may be colour coated by conventional methods. Preferably, hydroxypropyl methylcellulose makes up 56-58% w/w of the tablet, magnesium stearate makes up approximately 1% of the tablet, and darifenacin hydrobromide and anhydrous dibasic calcium phosphate make up the balance. The darifenacin hydrobromide content may range from 4mg-54mg per tablet, depending on the dose to be delivered. Such tablets would be suitable for administration once daily.

20

Preferably, the dosage forms of the present invention are adapted for oral administration, but they may also be adapted for rectal administration. Rectal suppository formulations may be prepared by dispersing the active ingredient in hardened oils or waxes using conventional methods.

25

According to another aspect of the invention, there is provided a method of treatment of irritable bowel syndrome or urinary incontinence, which comprises delivering darifenacin, or a pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of a patient in need of such treatment. The method may be performed by administering a dosage form of the invention to the gastrointestinal tract of a patient in need of such treatment.

30

The invention is illustrated by the following examples in which the following materials are used:

35

Methocel™ K4M - a high molecular weight hydroxypropyl methylcellulose with a number average in molecular weight of 89,000. It is classified in the USP as 2208 and a 2% solution in water has a nominal viscosity of 4000cps. It has a methoxy content of 19-24% and a hydroxypropoxy content of 7-12%;

- 5 Methocel™ E4M - a high molecular weight hydroxypropyl methylcellulose with a number average molecular weight of 93,000. It is classified in the USP as 2910 and a 2% solution in water has a nominal viscosity of 4000cps. It has a methoxy content of 28-30% and a hydroxypropoxy content of 7-12%;

- Methocel™ K100LV - a low molecular weight hydroxypropyl methylcellulose. It is
10 classified in the USP as 2208 and a 2% solution in water has a nominal viscosity of 100cps. It has a methoxy content of 19-24% and a hydroxypropoxy content of 7-12%;

Klucel EF™ - hydroxy propyl cellulose with a number average molecular weight of 60,000;

Ethocel™ - ethyl cellulose;

Avicel™ PH101 - microcrystalline cellulose with an average particle size of 50µm;

- 15 Lactose regular - lactose with a particle size equivalent to 110 mesh (137.5µm apertures);

Lactose Fast Flo™ - spray dried lactose; and

EmcomPress™ - dibasic calcium phosphate (anhydrous).

Aerosil 200 - colloidal anhydrous silica

20 Example 1 (comparative)

Fast release matrix tablet

Ingredient	Specification	mg/unit (theory)	g/batch (actual)
Darifenacin hydrobromide	Pfizer	23.810	30.19
Methocel K4M	Ph Eur	12.000	15.00
Methocel K100LV Premium	USP	28.000	35.00
Fast flo Lactose	Ph Eur	134.190	167.70
Magnesium Stearate	Ph Eur	2.000	2.50
	TOTAL	200.000mg	

- The Methocel K4M, K100LV premium, darifenacin and Fast-flo lactose were blended in a Turbula blender for 10 minutes. The mixture was then screened using a 30 mesh (500µm
25 apertures) screen and reblended for a further 10 minutes. Magnesium stearate was screened through a 30 mesh (500µm apertures) screen and added to the mixture before

blending for a further 5 minutes. The blend was then subjected to compression on a tableting machine using 8mm round normal convex tooling to make 1250 tablets.

Example 2

5 Medium release matrix tablet

Ingredient	Specification	mg/unit (theory)	g/batch (actual)
Darifenacin hydrobromide	Pfizer	23.810	30.19
Methocel K4M	Ph Eur	30.000	37.50
Methocel E4M	Ph Eur	30.000	37.50
Fast flo Lactose	Ph Eur	114.190	142.70
Magnesium Stearate	Ph Eur	2.000	2.50
	TOTAL	200.000mg	

The Methocel K4M, E4M, darifenacin and Fast-flo lactose were blended in a suitable blender for 10 minutes. The mixture was then screened using a 30 mesh (500µm apertures) screen and reblended for a further 10 minutes. Magnesium stearate was
 10 screened through a 30 mesh (500µm apertures) screen and added to the mixture before blending for a further 5 minutes. The blend was then subjected to compression on a tableting machine using 8mm round normal convex tooling to make 1250 tablets.

Example 3

15 Slow release matrix tablet

Ingredient	Specification	mg/unit (theory)	g/batch (actual)
Darifenacin hydrobromide	Pfizer	23.810	30.19
Anhydrous dibasic calcium phosphate	USP	59.790	74.70
Methocel K4M	Ph Eur	114.400	143.00
Magnesium Stearate	Ph Eur	2.000	2.50
	TOTAL	200.000	

The Methocel K4M, darifenacin and anhydrous dibasic calcium phosphate were blended in a Turbula blender for 10 minutes. The mixtur was then screened using a 30 mesh

(500 μ m apertures) screen and reblended for a further 10 minutes. Magnesium stearate was screened through a 30 mesh (500 μ m apertures) screen and added to the mixture before blending for a further 5 minutes. The blend was then subjected to compression on a tableting machine using 8mm round normal convex tooling to make 1250 tablets.

5

Example 4

Encapsulated coated core multiparticulates

(a) Preparation of uncoated cores

Ingredient	Specification	g/kg (theory)	g/batch (actual)
Darifenacin hydrobromide	Pfizer	119.048	119.76
Avicel PH101	Ph Eur	359.499	359.50
Lactose Regular	Ph Eur	359.499	359.50
Fumaric acid	NF	161.954	161.95
Purified water	Ph Eur	(500.000)	500.0
	TOTAL	1000.000g	1000.71

- The Avicel PH101, lactose regular, darifenacin and fumaric acid were blended in an Apex 2L Y cone for 10 minutes. The mixture was then screened using a 30 mesh (500 μ m apertures) screen and re-blended for 10 minutes. Purified water was added to form a wet mass amenable to extrusion. The resultant wet mass was extruded using an Nica E 140 extruder (1mm screen) and then spheronised using a Caleva spheroniser to form multiparticulate beads. The beads were then dried using a bed temperature of 50°C for 1 hour to remove excess moisture.

(b) Preparation of final formulation

Ingredient	Specification	mg/unit (theory)	g/batch (actual)
Darifenacin uncoated cores	Pfizer	200.000	150.30
Ethyl cellulose N-10	NF	17.750	13.32
Klucel EF	NF	7.250	5.44
Ethyl Acetate	NF	237.500	178.2
Isopropyl alcohol	NF	237.500	178.1
	TOTAL	225.000	

Filled into white size 2 gelatine capsule shells.

- Ethyl acetate and isopropyl alcohol were stirred in a suitable vessel to ensure thorough mixing. To this mixture the Klucel EF and ethyl cellulose N10 were added and the solution stirred until complete dissolution had taken place. The uncoated beads were added to a fluidised bed coater and using an inlet temperature of 40°C the beads were coated with the solution containing the Klucel EF and ethylcellulose N10. On completion of coating the beads were dried for 10 minutes using a bed temperature of approximately 50°C. The coated beads were filled into capsule shells prior to administration.

Example 5

10 Ion exchange resin formulation

Ingredient	g/batch
Darifenacin hydrobromide	60.39
Sodium polystyrene sulphonate	187.00
Disodium edetate, dihydrate	1.53
Water	2000.00

- The disodium edetate and sodium polystyrene sulphonate were suspended in water. This suspension was then heated to 50°C whilst stirring. The darifenacin hydrobromide was then added to the suspension and the suspension stirred for a further 2 hours at 50°C.
- 15 The darifenacin polystyrene sulphonate was then filtered off and washed until free of bromide ions. The darifenacin resinate was then dried under vacuum at 25°C for approximately 16 hours.

Example 6 (comparative)

20 Immediate Release Capsule 7.5mg

Ingredient	Specification	mg/unit theory	g/batch (actual)
Darifenacin hydrobromide	Pfizer	8.929	547.46
Lactose	Ph Eur	104.453	6267.20
Maize starch	Ph Eur	34.818	2089.10
Aerosil 200	Ph Eur	0.300	18.00
Magnesium stearate	Ph Eur	1.500	84.88
TOTAL		150.000	

1467.2g of the lactose was added to all of the darifenacin hydrobromide and blended in an Apex 8L double cone tumbling blender for 20 minutes. This was then milled using a Fitzmill (hammers forward, high speed) through a 1mm screen and the mill washed with the remaining lactose (4600.0g). This lactose, Aerosil 200 and maize starch were then
5 added to the darifenacin hydrobromide/lactose preblend prepared initially and blended for 20 minutes in a Gardner 28L double cone tumbling blender. This blend was then passed through a 1mm screen using a Fitzmill (knives forward, slow speed) and then blended for a further 20 minutes using the 28L blender. Magnesium stearate (88.88g) was then added and blending continued using the 28L blender for 5 minutes. The final blend was
10 then encapsulated into size 2 hard gelatin capsule shells using a Zanasi capsule filling machine.

Example 7

Measurement of *in vitro* release rates

15

Dissolution methods

Dissolution of the formulations of Examples 1-4 was performed using a rotating basket apparatus (Apparatus 1, USPXXII, p. 1578). The formulations were placed in baskets (40 mesh, 381µm apertures) using a rotation speed of 100rpm in 900ml water at 37°C +/-
20 0.5°C. At specified time intervals, 10ml aliquots were removed from the dissolution vessel from a zone midway between the surface of the dissolution medium and the top of the basket not less than 1cm from the vessel wall. The first 7ml is discarded and the remaining solution transferred to an HPLC vial for subsequent analysis.

25 The release of darifenacin from the formulation of Example 5 was determined according to USP XXIII Apparatus 4 (page 1794). Using a flow rate of 250ml/hour solutions at 37°C of the following pH were used to assess release:
0-1hr pH 1.5; 1-2hr pH 2.5; 2-3.5hr pH 4.5; 3.5-5hr pH 6.9; 5-24hr pH 7.2.

30 Dissolution of the formulation of Example 6 was performed using a rotating basket apparatus (Apparatus 1, USPXXII, p 1578). The formulations were placed in baskets (40mesh, 381µm apertures) using a rotation speed of 100rpm in 900ml water at 37°C +/- 0.5°C. At specified time intervals a 20ml aliquot of dissolution media was removed from a zone midway between the surface of the dissolution media and the top of the basket not
35 less than 1cm from the vessel wall. The aliquots were filtered (0.45µm, Acrodisc) and the

first 5ml of filtrate discarded. 5ml of the remaining filtrate was then diluted to 25ml using a 1:1 (v/v) solution of water/methanol prior to analysis by HPLC.

Analysis

- 5 For the formulations of Examples 1-5, High Performance Liquid Chromatography (HPLC) was performed using a BDS Hypersil C18 column. The mobile phase used was an aqueous 0.03M potassium dihydrogen orthophosphate at pH 3.5/methanol, (1000:800 v/v) using a flow rate of 1.5ml/min at 37°C and a sample size of 20 μ L. Detection was by fluorescence operating at an excitation wavelength of 288nm (slit width 18nm) and an
10 emission wavelength of 320nm (slit width 18nm).

- For the formulation of Example 6, High Performance Liquid Chromatography (HPLC) was performed using a Novapack C18 column. The mobile phase was aqueous 0.01M sodium acetate containing 0.2%v/v triethylamine at pH 6.0/methanol/acetonitrile (45:54:1,
15 v/v/v) using a flow rate of 1.0ml/min and a sample size of 50 μ L. Detection was by ultraviolet spectroscopy at 230nm.

Results

Example 1 formulation (comparative)

20	<u>Time (h)</u>	<u>% release (range)</u>
	1	65 (52-81)
	2	80 (72-92)
	4	91 (87-96)

25 Example 2 formulation

	<u>Time (h)</u>	<u>% release</u>
	1	41 (38-46)
	4	77 (73-81)
	8	95 (94-96)

30

Example 3 formulation

	<u>Time (h)</u>	<u>% release</u>
	1	6 (5-7)
	8	42 (36-44)
35	16	67 (59-70)

Example 4 formulation

	<u>Time (h)</u>	<u>% release</u>
	1	11 (9-15)
5	4	58 (50-70)
	8	98 (95-103)

Example 5 formulation

	<u>Time (h)</u>	<u>% release</u>
10	1	11 (10-12)
	2	25 (24-27)
	6	55 (51-59)
	12	79 (77-82)
	18	90 (89-91)
15	24	94 (93-95)

Example 6 formulation (comparative)

	<u>Time (h)</u>	<u>% release</u>
	0.25	94
20	0.5	99
	0.75	98

Example 8Clinical Pharmacokinetics Study

- 25 A four way, multiple dose crossover study to investigate the bioavailability of darifenacin and its 3'-hydroxy metabolite when given as a sustained release formulation compared with an immediate release formulation was carried out. Thirteen normal males received the formulations of Examples 1-3 od each for 6 days as well as the formulation of Example 6 three times a day. Plasma samples for drug and metabolite assay were taken
- 30 over 24 hours on the last day of dosing for each period of the study. The pharmacokinetic parameters (area under the concentration-time curve over 24 hours, AUC, maximum concentration and concentration at 24 hours post dose) were obtained for both drug and metabolite. The table below shows the ratio of AUC values for darifenacin and metabolite ($AUC_{\text{darifenacin}}/AUC_{\text{metabolite}}$) and the relative bioavailability of darifenacin ($F_{\text{rel darifenacin}}$) and
- 35 metabolite ($F_{\text{rel metabolite}}$) for the formulations versus an immediate release capsule.

Ratio of AUC of darifenacin: metabolite and relative bioavailability (F_{rel})
versus an immediate release capsule

Formulation:	Example 6 (immediate release)	Example 1	Example 2	Example 3
Ratio of AUC_{dar}/AUC_{met}	0.66	0.58	0.82	1.03
F_{rel} darifenacin	na	0.88	1.10	1.17
F_{rel} metabolite	na	0.98	0.82	0.70

5

na = Not applicable

These data indicate that the relative bioavailability of darifenacin over the metabolite is increased when darifenacin is administered in a sustained release formulation according

10 to the invention.

Claims:

1. A pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof,
5 and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the dosage form is adapted to deliver at least 10% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of the patient.
2. A dosage form as claimed in claim 1, which is adapted to deliver at least 50% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower
10 gastrointestinal tract.
3. A dosage form as claimed in claim 1 or claim 2, which is adapted to release the darifenacin, or the pharmaceutically acceptable salt thereof, to the gastrointestinal tract of the patient over or after a sustained period of time following administration of the dosage form to the patient.
- 15 4. A dosage form as claimed in claim 3, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released 4 hours after dosing.
5. A dosage form as claimed in claim 4, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released 8 hours after
20 dosing.
6. A dosage form as claimed in claim 5, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released 16 hours after dosing.
7. A pharmaceutical dosage form adapted for administration to the gastrointestinal
25 tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the dosage form is adapted to release the darifenacin, or the pharmaceutically acceptable salt thereof, in Apparatus 1 described in USP XXII at page 1578, having baskets of 40 mesh (381 μ m apertures), a rotation speed of 100 rpm and a dissolution medium of water
30 at 37°C, over a sustained period of time.
8. A dosage form as claimed in claim 7, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released after 4 hours.
9. A dosage form as claimed in claim 7, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released after 8 hours.

10. A dosage form as claimed in claim 7, wherein no more than 90% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, is released after 16 hours.
11. A dosage form as claimed in any one of the preceding claims, wherein the darifenacin is in the form of its hydrobromide salt.
- 5 12. A dosage form as claimed in any one of the preceding claims, which is adapted for oral administration.
13. A dosage form as claimed in any one of the preceding claims, wherein the darifenacin, or the pharmaceutically acceptable salt thereof, is embedded in a matrix from which it is released by diffusion.
- 10 14. A dosage form as claimed in any one of the preceding claims, wherein the matrix material is high molecular weight hydroxypropyl methylcellulose.
15. A dosage form as claimed in any one of claims 1-11, which is adapted for rectal administration.
16. A dosage form as claimed in claim 15, which is a suppository.
- 15 17. A process for the production of a dosage form as defined in claim 14, which comprises mixing darifenacin, or a pharmaceutically acceptable salt thereof, with high molecular weight hydroxypropyl methylcellulose.
18. A method of treatment of irritable bowel syndrome or urinary incontinence, which comprises delivering darifenacin, or a pharmaceutically acceptable salt thereof, to the
- 20 lower gastrointestinal tract of a patient in need of such treatment.
19. A method as claimed in claim 18, which comprises administering a dosage form as defined in any one claims 1-16 to the gastrointestinal tract of a patient in need of such treatment.

INTERNATIONAL SEARCH REPORT

Inter national Application No
PCT/EP 96/03719

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/40 A61K9/16 A61K9/20 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 388 054 (PFIZER INC.,U.S.A.) 19 September 1990 cited in the application see claims 1,8-12 see page 7, line 8 - line 24 ---	1-19
A	WO,A,95 19164 (PFIZER RESEARCH AND DEVELOPMENT COMPANY N.V./S.A.,BE/IE) 20 July 1995 see claims 2-6 see page 1, line 30 - line 31 see page 2, line 8 - line 10 see page 3, line 10 - line 26 -----	1-19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

2 December 1996

Date of mailing of the international search report

11.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 96/03719

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 18,19
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/03719

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-388054	19-09-90	AU-B- 614224	22-08-91
		AU-A- 5140290	20-09-90
		CA-A,C 2012295	17-09-90
		CN-A,B 1045580	26-09-90
		CZ-A- 9001295	17-05-95
		CY-A- 1812	20-10-95
		DE-D- 69004302	09-12-93
		DE-T- 69004302	24-02-94
		EG-A- 18951	30-03-94
		ES-T- 2060020	16-11-94
		FI-B- 95573	15-11-95
		HK-A- 130294	02-12-94
		IE-B- 62515	08-02-95
		IL-A- 93694	26-08-94
		JP-A- 2282360	19-11-90
		JP-B- 7064809	12-07-95
		JP-A- 7149640	13-06-95
		NO-B- 176316	05-12-94
		PL-B- 164136	30-06-94
		PT-B- 93443	29-02-96
		SG-A- 143394	13-01-95
		SU-A- 1833374	07-08-93
		RU-C- 2015965	15-07-94
		US-A- 5096890	17-03-92
		US-A- 5233053	03-08-93
WO-A-9519164	20-07-95	AU-A- 1455395	01-08-95